Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: Impact of nodal density and total tumor volume

Japanese Journal of Clinical Oncology

Volumn 36, Issue 9, 2006, Pages 537-546

  Chufal, Kundan S ^a   Rastogi, Madhup ^b   Srivastava, Madhu ^b   Pant, M C ^b   Bhatt, M L B ^b   Srivastava, Kirti ^b  

^a Batra Hospital India   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Chemoboost; Concurrent; Head and neck cancer; Nodal density; Total tumor volume

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; INDEPENDENT VARIABLE; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHARYNGITIS; PROGNOSIS; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR BURDEN;

EID: 33750108195     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl081     Document Type: Article

References (27)

1. Fletcher GH. Textbook of Radiotherapy, 3rd edn. Philadelphia, PA: Lea and Febiger 1980;103-80.
2. Johnson CR, Khandelwal SR, Schmidt-Ulrich RK, Ravalese J 3rd, Wazer DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995;32:635-41.
3. Mancuso AA, Harnsberger HR, Muraki AS, Stevens MH. Computed tomography of cervical and retropharyngeal lymph nodes: Normal anatomy, variants of normal, and applications in staging head and neck cancer. Part I: Normal anatomy. Radiology 1983;148:709-14.
4. Bergeron RT, Osborn AG, Som PM. Head and Neck imaging. St Louis, Mo: CV Mosby Co 1984.
5. Pierre Moreau, Yves G, Jacques C. Computed tomography of metastatic cervical lymph nodes. A clinical, computed tomographic, pathological correlative study. Arch Otolaryngol Head Neck Surg 1990;116:1190-3.
6. Munck JN, Cvitkovic JD, Piekarski JD, Benhamou E, Recondo G, Bachouchi M, et al. Computed tomo-graphic density of metastatic lymph nodes as a treatment related prognostic factor in advanced head and neck cancer. J Natl Cancer Inst 1991;83:569-75.
7. Janot F, Cvitkovic E, Piekarski JD, Sigal R, Armand JP, Bensmaine A, et al. Correlation between nodal density in contrasted scans and response to cisplatin based chemotherapy in head and neck squamous cell cancer: A prospective validation. Head Neck 1993;15:222-9.
8. Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P, et al. Nodal Chemotherapy density and total tumor volume as prognostic gactors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998;47:175-83.
9. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxy-genation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
10. Overgaard, J. Importance of tumor hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother Oncol 1992;24:S64.
11. Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML. Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: A pragmatic approach for locally advanced head and neck squamous cell carcinoma. Oral Oncol 2006;42:517-25.
12. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
13. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization, Offset Publication No. 48; 1979.
14. Wang HM, Ng SH, Wang CH, Liaw MH, Lai GM. Correlation between computed tomographic density of lymph node metastases and response to cisplatin based chemotherapy in patients with head and neck squamous cell carcinoma in an area in which betel chewing is prevalent. Cancer 1996;78:1972-9.
15. Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R, et al. Oxygenation of head and neck tumors. Cancer 1993;71:2319-25.
16. Corry J, Rischin D, Smith JG, D'Costa IA, Huges PG, Sexton MA, et al. Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer. Radiother Oncol 2000;54:123-7.
17. Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, et al. Phase I/II trial of radiation with chemotherapy 'boost' for advanced squamous cell carcinomas of the head and neck: Toxicities and responses. J Clin Oncol 1999;17:2390-5.
18. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23:79-87.
19. Rastogi M, Srivastava M, Chufal KS, Pant MC, Srivastava K, Bhatt MB. Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma. Jpn J Clin Oncol 2005;35:572-9.
20. Van den Bogaert W, van der Schueren E, Horiot JC, De Vilhena M, Schraub S, Svoboda V, et al. The EORTC trial on three fractions per day and misonidazole in advanced head and neck cancer: Prognostic factors. Radiother Oncol 1995;35:100-6.
21. Collins CD, Constant O, Fryatt I, Blake PR, Parsons CA. Relationship of computed tomography tumor volume to patient survival in carcinoma of the cervix treated by radical radiotherapy. Br J Radiol 1994;67:252-6.
22. Carl J, Andersen LJ, Pedersen M, Greisen O. Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx. Radiother Oncol 1996;39:229-33.
23. Hjelm-Hansen M, Jorgensen K, Andersen AP, Lund C. Laryngeal, carcinoma II. Analysis of treatment results using the Ellis model. Acta Radiol Oncol Radiat Phys Biol 1979;18:385-407.
24. Freeman DE, Mancuso AA, Parsons JT, Mendenhall WM, Million RR. Irradiation alone for supraglottic larynx carcinoma: Can CT findings predict treatment results? Int J Radiat Oncol Biol Phys 1990;19:485-490.
25. Pameijer FA, Mancuso AA, Mendenhall WM, Parsons JT, Kubilis PS. Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? Int J Radiat Oncol Biol Phys 1997;37:1011-21.
26. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): Results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64:77-82.
27. Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: A multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003;56:399-412.